Drugs / 2-methoxyestradiol
2-methoxyestradiol
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00028821 | Jan 2002 → Apr 2006 | cancer of unknown primary site, plasma cell myeloma, refractory plasma cell neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00030095 | Sep 2001 → ? | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT00481455 | Apr → Sep 2007 | glioblastoma | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00444314 | Feb 2007 → Dec 2008 | renal cell carcinoma | CASI pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT00394810 | Nov 2006 → Nov 2008 | prostate cancer | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00328497 | May 2006 → Dec 2008 | carcinoid tumor | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00306618 | Jan 2006 → Nov 2007 | glioblastoma | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00592579 | Mar 2001 → Sep 2008 | smoldering plasma cell myeloma | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2012-12-04 | CASI pharmaceuticals, Inc. | Results PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis issuerdirect.com ↗
In this study, we demonstrated that 2ME2, an endogenous metabolite of estradiol, significantly inhibits lymphocyte activation and proliferation and dramatically suppresses development of experimental MS. |
| 2008-11-03 | CASI pharmaceuticals, Inc. | Results Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models issuerdirect.com ↗
Results from treatment studies in a preclinical model of established rheumatoid arthritis demonstrated that daily oral administration of 2ME2 suppressed both clinical and radiographic indicators of joint inflammation and damage, including soft tissue swelling and bone erosion. |
| 2008-01-28 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study issuerdirect.com ↗
Results demonstrate that the combination of Panzem(R) NCD and Avastin(R) is well tolerated in advanced carcinoid tumor patients. |
| 2007-12-11 | CASI pharmaceuticals, Inc. | Regulatory EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis issuerdirect.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Panzem(R) (2-Methoxyestradiol or 2ME2) in rheumatoid arthritis (RA). |
| 2007-10-24 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study issuerdirect.com ↗ |
| 2007-06-06 | CASI pharmaceuticals, Inc. | Results Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO issuerdirect.com ↗
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced the presentation of interim data from the Phase 1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) in combination with Taxol(R) (paclitaxel) in patients with metastatic breast cancer. |
| 2007-06-05 | CASI pharmaceuticals, Inc. | Results Phase 2 Results for EntreMed's Panzem(R) NCD Brain Cancer Study Presented at ASCO issuerdirect.com ↗ |
| 2007-06-04 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma issuerdirect.com ↗
Results of the Phase 2 study demonstrated prolonged stable disease and minor responses in patients receiving the original formulation of Panzem(R) Capsules. |
| 2007-03-26 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds issuerdirect.com ↗
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of comparative mechanism of action data for its three lead clinical stage compounds Panzem(R), MKC-1 and ENMD-1198. |
| 2006-12-21 | CASI pharmaceuticals, Inc. | Results EntreMed's Panzem(R) Demonstrates Antitumor Activity in Brain Tumor Model issuerdirect.com ↗ |
| 2006-12-12 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma issuerdirect.com ↗ |
| 2006-11-14 | CASI pharmaceuticals, Inc. | Results EntreMed Data Highlights Antiangiogenic Role Of 2ME2 In Rheumatoid Arthritis issuerdirect.com ↗ |
| 2006-06-28 | CASI pharmaceuticals, Inc. | Regulatory EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma issuerdirect.com ↗
EntreMed, Inc. (Nasdaq: ENMD) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead drug candidate, 2-methoxyestradiol (2ME2 or Panzem(R)), for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. |
| 2006-06-22 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Data Demonstrating Antiangiogenic Activity of 2ME2 in Rheumatoid Arthritis issuerdirect.com ↗
Results from studies in a preclinical arthritis model of chronic autoimmune inflammatory joint disease demonstrated that daily oral administration of 2ME2 resulted in a statistically significant reduction in clinical severity of joint inflammation and inhibition of articular joint damage as determined by blinded high resolution radiographs of bone erosions. |
| 2006-04-03 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Preclinical Results at AACR for Panzem(R) and ENMD-1198 issuerdirect.com ↗
Preclinical studies demonstrate that 2ME2 can be combined with maximally tolerated doses (MTD) of standard chemotherapeutic agents without additive toxicity, resulting in greater antitumor activity than either agent alone. |
| 2006-03-22 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Preclinical Data Supporting 2ME2's DMARD Activity in Rheumatoid Arthritis issuerdirect.com ↗
Preclinical studies demonstrate that daily oral administration of 2ME2 resulted in a dose-dependent decrease in inflammation and tissue destruction in accepted models of rheumatoid arthritis. |
| 2005-11-16 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Panzem(R) NCD Phase Ib Clinical Trial Results issuerdirect.com ↗
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced interim results for two Phase Ib studies for its lead clinical-stage drug candidate, Panzem(R) NCD, in patients with advanced cancer. |
| 2005-10-10 | CASI pharmaceuticals, Inc. | Results EntreMed Reports 2ME2 Inhibits Inflammation and Disease Progression In Rheumatoid Arthritis Model issuerdirect.com ↗
Results from preclinical studies in a rat collagen-induced arthritis model of chronic autoimmune inflammatory joint disease demonstrated that daily oral administration of 2ME2 resulted in a statistically significant reduction in clinical severity of joint inflammation and inhibition of articular joint damage as determined by blinded high resolution radiographs of bone erosions. |
| 2005-09-27 | CASI pharmaceuticals, Inc. | Results Panzem(R) Demonstrates Safety and Clinical Benefit in Hormone Refractory Prostate Cancer issuerdirect.com ↗
today announced the publication of results of the multi-center Phase II study for Panzem(R) capsules (2ME2, 2-methoxyestradiol) in hormone refractory prostate cancer. |
| 2005-08-23 | CASI pharmaceuticals, Inc. | Results Disease Modifying Activity of 2ME2 Demonstrated in Preclinical Rheumatoid Arthritis Studies issuerdirect.com ↗
today announced the presentation of positive preclinical results for its lead compound, 2-methoxyestradiol (2ME2), in models of rheumatoid arthritis. |
| 2005-07-06 | CASI pharmaceuticals, Inc. | Results Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer Models issuerdirect.com ↗
Results demonstrated that 2ME2 and 2ME2 analogs effectively inhibited the in vitro growth of 19 distinct NSCLC and SCLC cell lines. |
| 2005-04-14 | CASI pharmaceuticals, Inc. | Regulatory EntreMed Granted FDA Orphan Drug Status for Panzem(R) (2ME2) in Ovarian Cancer issuerdirect.com ↗ |
| 2005-04-12 | CASI pharmaceuticals, Inc. | Results Disease Modifying Activity of 2ME2 in Rheumatoid Arthritis Validated in Second Preclinical Study issuerdirect.com ↗ |
| 2005-04-05 | CASI pharmaceuticals, Inc. | Results EntreMed Presents Preclinical Data for 2ME2 in Rheumatoid Arthritis issuerdirect.com ↗
Data from the study demonstrated that oral treatment with 2ME2 resulted in a dose-dependent decrease in severity of arthritic disease as determined by standard clinical measurements. |
All press releases naming this drug 39 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-methoxyestradiol | “This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2)...” NCT00306618 ↗7“We conducted a multicenter phase II study to evaluate the objective response rate of 2-methoxyestradiol (2ME2 NCD) alone and in combination with sunitinib for patients with...” PMID 21174224 ↗ Dec 2010 “A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).” PMID 20499131 ↗ May 2010 “2-methoxyestradiol” NCT00481455 ↗ |
| Known as | 2-methoxyoestradiol | ChEMBL registry synonym — accepted as the source's own label CHEMBL299613 ↗ |
| Known as | 2ME2 | “2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties.” PMID 17947482 ↗ Oct 20072“PURPOSE: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity.” PMID 20499131 ↗ May 2010 “A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors” NCT00030095 ↗ |
| Known as | 2ME2 NCD | “We conducted a multicenter phase II study to evaluate the objective response rate of 2-methoxyestradiol (2ME2 NCD) alone and in combination with sunitinib for patients with...” PMID 21174224 ↗ Dec 2010 |
| Known as | NSC-659853 | “A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors” NCT00030095 ↗ |
| Known as | Panzem | “This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2)...” NCT00306618 ↗1“PURPOSE: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity.” PMID 20499131 ↗ May 2010 |
| Modality | Small molecule | — CHEMBL299613 ↗ |
| Route | Oral | “Patients receive oral 2-methoxyestradiol (2-ME) once daily.” NCT00028821 ↗ |